CPM

Across TCGA pan-cancer cohorts, CPM mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CPM data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher CPM mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CPM expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

GBM, PDAC, and HNSC are the cancer types where CPM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Quartile	All	0.638	0.840	.014	13	view →
PDAC	OS	Quartile	III,IV	0.297	0.736	.006	12	view →
HNSC	OS	Median	All	1.000	0.449	.023	10	view →
CCRCC	OS	Tertile	All	0.882	0.693	.034	2	view →
LSCC	DFS	Median	III,IV	1.000	0.867	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CPM–GBM (DFS)

Open the GBM breakdown →